Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 immunohistochemistry (IHC) expression In patients with HER2-low, hormone receptor (HR)-positive, early-stage breast cancer in the phase 2 TRIO-US B-12 TALENT trial.
The trial included 58 patients with HER2-low, HR-positive, operable stage II to III early breast cancer. Patients were randomly assigned in a 1:1 fashion to receive T-DXd alone (n=29) or T-DXd plus anastrozole or